公开(公告)号：US08468342B2

公开(公告)日：2013-06-18

申请号：US12083894

申请日：2006-03-15

申请人： Yi Zhang ,  Jian Zhou ,  Zhenxin Xi ,  Hongping Tian

发明人： Yi Zhang ,  Jian Zhou ,  Zhenxin Xi ,  Hongping Tian

IPC分类号： G06F7/20 ,  G06F11/30

CPC分类号： G06F21/577 ,  G06F11/2284

摘要： The present invention proposes a computer system and a method capable of performing integrity detection, comprising: a running mode unit which comprises an integrity detection boot variable to determine whether or not to initiate an integrity detection boot mode by judging said running mode unit; an EFI integrity detection unit (5), which is used for performing an integrity detection on EFI image codes in the integrity detection boot mode, and comprises an integrity metric value for being compared with an EFI integrity calculated value generated after the EFI integrity detection unit performs the integrity detection on the EFI image codes, to determine the integrity of the EFI image codes; an operating system integrity detection unit (6); and an integrity management unit. The present invention is based on the EFI BIOS to perform the integrity detection on the operating system during the pre-boot stage, having better reliability and security.

摘要翻译： 本发明提出一种能够执行完整性检测的计算机系统和方法，包括：运行模式单元，其包括完整性检测引导变量，以通过判断所述运行模式单元来确定是否启动完整性检测引导模式; EFI完整性检测单元（5），其用于对完整性检测引导模式中的EFI图像代码执行完整性检测，并且包括与EFI完整性检测单元之后生成的EFI完整性计算值进行比较的完整性度量值 对EFI图像代码执行完整性检测，以确定EFI图像代码的完整性; 操作系统完整性检测单元（6）; 和诚信管理单位。 本发明基于EFI BIOS，以在预引导阶段对操作系统执行完整性检测，具有更好的可靠性和安全性。

公开(公告)号：US20130144035A1

公开(公告)日：2013-06-06

申请号：US13642670

申请日：2011-04-21

申请人： Dongfeng Pan ,  Stuart S. Berr ,  Yi Zhang

发明人： Dongfeng Pan ,  Stuart S. Berr ,  Yi Zhang

IPC分类号： A61K51/08

CPC分类号： A61K51/088 ,  A61K49/0002 ,  A61K49/0034 ,  A61K51/06

摘要： The present application discloses a new multivalent peptide ligand specifically targeting polymorphonuclear leukocytes (PMNs) with favorable pharmacological parameters to monitor sites of inflammation for imaging. The detailed synthesis, characterization, and pharmacological evaluation of the ligands are reported here. Two separate peptide binding ligands for formyl peptide and tuftsin receptors were chosen to link together based on the high expression levels of the two receptors on activated PMNs The heterobivalency and pegylated links were incorporated in the structural design to improve the sensitivity of the detection and to improve the bioavailability along with blood clearance profile, respectively. Two chemical constructs: cFLFLF-(PEG)n-TKPPR-99mTc (n=4, 12) were evaluated in vitro with human PMNs for binding affinity and bioavailability. As a result, FLFLF-(PEG)12-TKPPR99mTc was found to have more favorable pharmacological properties and was therefore used for further in vivo studies. Preliminary in vivo assessment of the agent was performed using Single Gamma Emission Computed Tomography (SPECT) imaging of a mouse model of ear inflammation. The results of these studies indicate cFLFLF-(PEG)12-TKPPR-99mTc may be a desirable imaging agent for binding to PMNs to identify sites of inflammation by SPECT.

摘要翻译： 本申请公开了一种特异靶向多形核白细胞（PMN）的新型多价肽配体，具有良好的药理学参数，用于监测成像的炎症部位。 这里报道了配体的详细合成，表征和药理学评估。 基于激活的PMN上的两种受体的高表达水平，选择两种单独的用于甲酰肽和簇状蛋白受体的肽结合配体连接在一起。将异源和聚乙二醇化的链接并入结构设计中，以提高检测的灵敏度和改善 分别具有生物利用度和血液清除曲线。 两种化学构建体：cFLFLF-（PEG）n-TKPPR-99mTc（n = 4,12）在体外用人PMNs进行了评估，用于结合亲和力和生物利用度。 结果发现FLFLF-（PEG）12-TKPPR99mTc具有更好的药理学特性，因此用于进一步的体内研究。 使用单发伽马发射计算机断层扫描（SPECT）成像小鼠耳炎的模型进行药物的初步体内评估。 这些研究的结果表明，cFLFLF-（PEG）12-TKPPR-99mTc可能是用于结合PMN的理想显像剂，以通过SPECT鉴定炎症部位。

公开(公告)号：US20130116578A1

公开(公告)日：2013-05-09

申请号：US13726786

申请日：2012-12-26

申请人： Qi An ,  Pramodsingh Hirasingh Thakur ,  Viktoria A. Averina ,  Yi Zhang ,  Robert J. Sweeney

发明人： Qi An ,  Pramodsingh Hirasingh Thakur ,  Viktoria A. Averina ,  Yi Zhang ,  Robert J. Sweeney

IPC分类号： A61B5/0205

CPC分类号： A61B5/0205 ,  A61B5/0031 ,  A61B5/02007 ,  A61B5/024 ,  A61B5/0816 ,  A61B5/4842 ,  A61B5/7275 ,  A61N1/37282 ,  G06F19/00 ,  G06Q10/00 ,  G06Q50/22 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50

摘要： A system comprises a risk analysis module and a worsening heart failure (WHF) detection module. The risk analysis module measures at least one first physiological parameter of a subject using a physiological sensor of an ambulatory medical device, and determines a heart failure (HF) risk score for the subject according to the at least one measured first physiological parameter. The HF risk score indicates susceptibility of the subject to experiencing a HF event. The WHF detection module measures at least one second physiological parameter of the subject using the same or different physiological sensor, and generates an indication of prediction that the subject will experience a WHF event when the at least one second physiological parameter satisfies a WHF detection algorithm. The risk analysis module adjusts generation of the indication by the WHF detection algorithm according to the determined HF risk score.

摘要翻译： 系统包括风险分析模块和恶化心力衰竭（WHF）检测模块。 风险分析模块使用移动医疗装置的生理传感器测量受试者的至少一个第一生理参数，并且根据至少一个测量的第一生理参数确定受试者的心力衰竭（HF）风险评分。 HF风险评分表示受试者经历HF事件的易感性。 WHF检测模块使用相同或不同的生理传感器测量受试者的至少一个第二生理参数，并且当至少一个第二生理参数满足WHF检测算法时，生成预测对象将经历WHF事件的指示。 风险分析模块根据确定的HF风险评分调整WHF检测算法生成指示。

公开(公告)号：US20130096035A1

公开(公告)日：2013-04-18

申请号：US13805625

申请日：2011-07-26

申请人： Tza-Huei Wang ,  Seungkyung Park ,  Samuel Yang ,  Yi Zhang

发明人： Tza-Huei Wang ,  Seungkyung Park ,  Samuel Yang ,  Yi Zhang

IPC分类号： C12Q1/68

CPC分类号： C12Q1/686 ,  C12Q1/6844 ,  C12Q2565/629

摘要： A fluidic cartridge for biochemical assays includes a cartridge body defining a first droplet region and a second droplet region with a droplet restraining barrier therebetween. The droplet restraining barrier has a gap between the first and the second droplet regions. The fluidic cartridge also includes a first droplet dispensed in the first droplet region. The first droplet includes a plurality of magnetic particles dispersed therein. The fluidic cartridge also includes a second droplet disposed in the second droplet region. The plurality of magnetic particles are sufficiently small to be drawn through the gap between the first and second droplet regions when compelled by an applied magnetic field, and the first droplet is restrained by the restraining barrier while the plurality of magnetic particles are drawn through the gap. A biochemical assay system includes a stage adapted to receive a fluidic cartridge, and a magnetic control assembly that includes a magnet. The magnet of the magnetic control assembly is movable to direct motion of magnetic particles contained within the fluidic cartridge.

摘要翻译： 用于生物化学测定的流体盒包括限定第一液滴区域的盒体和在其间具有液滴限制屏障的第二液滴区域。 液滴限制屏障在第一和第二液滴区域之间具有间隙。 流体盒还包括分配在第一液滴区域中的第一液滴。 第一液滴包括分散在其中的多个磁性颗粒。 流体盒还包括设置在第二液滴区域中的第二液滴。 当被施加的磁场强迫时，多个磁性颗粒足够小以便被吸入第一和第二液滴区域之间的间隙，并且第一液滴被约束屏障约束，同时多个磁性颗粒被吸引通过间隙 。 生物化学测定系统包括适于接收流体盒的阶段和包括磁体的磁性控制组件。 磁性控制组件的磁体可移动以引导包含在流体盒内的磁性颗粒的运动。

公开(公告)号：US08401636B2

公开(公告)日：2013-03-19

申请号：US13209938

申请日：2011-08-15

申请人： Yi Zhang ,  John D. Hatlestad ,  Gerrard M. Carlson ,  Yousufali Dalal ,  Marina V. Brockway ,  Kent Lee ,  Richard O. Kuenzler ,  Carlos Haro ,  Krzysztof Z. Siejko ,  Abhilash Patangay

发明人： Yi Zhang ,  John D. Hatlestad ,  Gerrard M. Carlson ,  Yousufali Dalal ,  Marina V. Brockway ,  Kent Lee ,  Richard O. Kuenzler ,  Carlos Haro ,  Krzysztof Z. Siejko ,  Abhilash Patangay

IPC分类号： A61N1/18

CPC分类号： A61M5/1723 ,  A61B5/02055 ,  A61B5/0215 ,  A61B5/024 ,  A61B5/02405 ,  A61B5/053 ,  A61B5/0816 ,  A61B5/1116 ,  A61B5/686 ,  A61B5/7275 ,  A61N1/36114 ,  A61N1/36135 ,  A61N1/3621 ,  A61N1/365 ,  A61N1/36585 ,  G06F19/00

摘要： The health state of a subject is automatically evaluated or predicted using at least one implantable device. In varying examples, the health state is determined by sensing or receiving information about at least one physiological process having a circadian rhythm whose presence, absence, or baseline change is associated with impending disease, and comparing such rhythm to baseline circadian rhythm prediction criteria. Other chronobiological rhythms beside circadian may also be used. The baseline prediction criteria may be derived using one or more past physiological process observation of the subject or population of subjects in a non-disease health state. The prediction processing may be performed by the at least one implantable device or by an external device in communication with the implantable device. Systems and methods for invoking a therapy in response to the health state, such as to prevent or minimize the consequences of predicted impending heart failure, are also discussed.

摘要翻译： 使用至少一个可植入装置自动评价或预测受试者的健康状况。 在不同的实施例中，通过感测或接收关于至少一个具有昼夜节律的生理过程的信息来确定健康状况，所述生理过程的存在，不存在或基线变化与即将发生的疾病相关联，并将该节律与基线昼夜节律预测标准进行比较。 也可以使用昼夜节律以外的其他时间生理节律。 可以使用在非疾病健康状态下的受试者或受试者群体的一个或多个过去的生理过程观察来导出基线预测标准。 预测处理可以由至少一个可植入装置或与可植入装置通信的外部装置执行。 还讨论了响应于健康状态调用疗法的系统和方法，例如预防或最小化预期的即将到来的心力衰竭的后果。

公开(公告)号：US20130046493A1

公开(公告)日：2013-02-21

申请号：US13213899

申请日：2011-08-19

申请人： Bethany Hoogs ,  Jason Black ,  Yi Zhang ,  Weiwei Chen ,  Ming Li

发明人： Bethany Hoogs ,  Jason Black ,  Yi Zhang ,  Weiwei Chen ,  Ming Li

IPC分类号： G06F19/00

CPC分类号： G06Q10/0631 ,  G06Q10/04 ,  H02J3/00 ,  H02J2003/003 ,  H02J2003/007 ,  Y02E60/76 ,  Y02P90/82 ,  Y04S10/54 ,  Y04S40/22

摘要： Systems and methods for performing data anomaly detection and/or removal are usable to accurately assess baseline power consumption. According to one embodiment of the invention, a system can be provided. The system can be operable to receive energy consumption data of a location; select, based at least in part on a collection period of the energy consumption data, an algorithm for detecting anomalies in the energy consumption data; perform the algorithm on the energy consumption data to detect the anomalies in the energy consumption data; and determine an energy consumption baseline for the location based at least in part on a result of the algorithm.

摘要翻译： 用于执行数据异常检测和/或移除的系统和方法可用于准确评估基线功耗。 根据本发明的一个实施例，可以提供一种系统。 该系统可操作以接收位置的能量消耗数据; 至少部分地基于能量消耗数据的收集周期来选择用于检测能量消耗数据中的异常的算法; 执行能耗数据算法，检测能耗数据中的异常情况; 并且至少部分地基于所述算法的结果来确定所述位置的能量消耗基准。

公开(公告)号：US20130040840A1

公开(公告)日：2013-02-14

申请号：US13540211

申请日：2012-07-02

申请人： Hui Huang ,  Sukanta BANERJEE ,  Michael Seul ,  Nataliya Korzheva ,  Jiacheug Yang ,  Yi Zhang

发明人： Hui Huang ,  Sukanta BANERJEE ,  Michael Seul ,  Nataliya Korzheva ,  Jiacheug Yang ,  Yi Zhang

IPC分类号： C40B30/04 ,  C40B60/12 ,  C40B40/06

CPC分类号： C12Q1/6804 ,  G01N33/6803 ,  G01N33/6854 ,  G01N2333/705 ,  G01N2458/10 ,  C12Q2563/179

摘要： Compositions and methods of detecting multiple proteins of interest in a sample using arrays are provided herein.

摘要翻译： 本文提供了使用阵列检测样品中感兴趣的多种蛋白质的组合物和方法。

公开(公告)号：US08340764B2

公开(公告)日：2012-12-25

申请号：US13029631

申请日：2011-02-17

申请人： Tamara Colette Baynham ,  Yi Zhang ,  Joseph M. Pastore

发明人： Tamara Colette Baynham ,  Yi Zhang ,  Joseph M. Pastore

IPC分类号： A61B8/14

CPC分类号： A61N1/36514 ,  A61N1/3621 ,  A61N1/36521 ,  A61N1/36557 ,  A61N1/36564 ,  A61N1/36578 ,  A61N1/36585

摘要： A pacing system delivers cardiac protection pacing to protect the heart from injuries associated with ischemic events. The pacing system detects an ischemic event and, in response, initiates one or more cardiac protection pacing sequences each including alternative pacing and non-pacing periods. In one embodiment, the pacing system initiates cardiac protection pacing sequences including at least one postconditioning sequence to protect the heart from a detected ischemic event and a plurality prophylactic preconditioning sequences to protect the heart from probable future ischemic events.

摘要翻译： 起搏系统提供心脏保护起搏，以保护心脏免受与缺血事件相关的损伤。 起搏系统检测缺血事件，并作为响应启动一个或多个心脏保护起搏序列，每个起搏序列包括替代起搏和非起搏期。 在一个实施例中，起搏系统启动心脏保护起搏序列，包括至少一个后处理序列以保护心脏免受所检测的缺血事件和多个预防性预处理序列，以保护心脏免受可能的未来缺血事件。

公开(公告)号：US08334660B2

公开(公告)日：2012-12-18

申请号：US12783484

申请日：2010-05-19

申请人： Eric Li ,  Chun Lu ,  Yi Zhang

发明人： Eric Li ,  Chun Lu ,  Yi Zhang

IPC分类号： G05F1/00 ,  H05B37/02 ,  H05B39/04 ,  H05B41/36 ,  H05B39/02 ,  H05B37/00 ,  H05B39/00 ,  H05B41/00

CPC分类号： H05B33/0827

摘要： A driving circuit for regulating current in a light source using a tracking component. The tracking component detects the voltage difference between an input node in the input stage and an output node in the output stage. The input stage is connected to a current source and includes an input transistor. The output stage is connected to the light source and includes an output transistor. The tracking component generates an output that controls the input and output transistors based on the voltage difference between the input node and the output node so that the voltage at the input node tracks the voltage at the output node. By using the tracking component, the LED driver can achieve accurate current control through one output transistor instead of cascaded transistors, resulting in lower output operating voltage and reduced power dissipation of the LED driver. Further, the tracking component is intermittently operated or shared across different channels to reduce energy consumption of the LED driver.

摘要翻译： 一种用于使用跟踪部件调节光源中的电流的驱动电路。 跟踪组件检测输入级中的输入节点与输出级中的输出节点之间的电压差。 输入级连接到电流源并包括输入晶体管。 输出级连接到光源并包括输出晶体管。 跟踪组件产生输出，其基于输入节点和输出节点之间的电压差来控制输入和输出晶体管，使得输入节点处的电压跟踪输出节点处的电压。 通过使用跟踪组件，LED驱动器可以通过一个输出晶体管而不是级联晶体管实现精确的电流控制，从而降低输出工作电压并降低LED驱动器的功耗。 此外，跟踪部件在不同的通道间歇地操作或共享以减少LED驱动器的能量消耗。

公开(公告)号：US20120232934A1

公开(公告)日：2012-09-13

申请号：US13046501

申请日：2011-03-11

申请人： Yi Zhang ,  Harry Snyder

发明人： Yi Zhang ,  Harry Snyder

IPC分类号： G06Q40/00 ,  G06Q10/00

CPC分类号： G06Q10/10

摘要： Automated insurance policy form generation and completion includes electronically receiving one or more forms and receiving an indication that a particular form is an overflow form for a particular base form. The relationship between the overflow form and base form is recorded based on the received indication and the fields on the base form and overflow form are tagged according to a naming convention. The number of overflow forms to use is determined based on an amount of received data and by using the naming convention to determine a number of available fields on the base form and overflow forms.

摘要翻译： 自动保险单生成和完成包括以电子方式接收一个或多个表单，并接收特定表单为特定基本形式的溢出表单的指示。 根据接收到的指示记录溢出形式和基本形式之间的关系，并根据命名约定对基本格式和溢出形式上的字段进行标记。 要使用的溢出表单的数量是基于接收到的数据量确定的，并且通过使用命名约定来确定基本表单和溢出表单上的多个可用字段。